Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962167 · ClinicalTrials.gov registry record · Phase 1
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
A Phase 1 study of Atypical Teratoid/Rhabdoid Tumor and Medulloblastoma Recurrent, sponsored by Sabine Mueller, MD, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 8
- Study locations
NCT02962167: Completed Phase 1 study of Atypical Teratoid/Rhabdoid Tumor and Medulloblastoma Recurrent, sponsored by Sabine Mueller, MD, PhD.
NCT02962167 is a Phase 1 study of Atypical Teratoid/Rhabdoid Tumor and Medulloblastoma Recurrent that has completed, run by Sabine Mueller, MD, PhD. The registered enrollment target is 34 participants, below the 84-participant average among 9 other Atypical Teratoid/Rhabdoid Tumor trials with a reported enrollment target (60% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02962167, a Phase 1 study of Atypical Teratoid/Rhabdoid Tumor and Medulloblastoma Recurrent, has completed, sponsored by Sabine Mueller, MD, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT).
Primary Outcome
The safety of the modified measles virus will be assessed by monitoring for adverse events. Subjects will be monitored for adverse events via scheduled laboratory assessments, vital sign measurements, and physical examinations. The severity of any toxicity will be graded according to the NCI CTCAE v5.0. We will aggregate this information into the number of subjects with adverse events that are related to study treatment.
Conditions Studied
Interventions
- BIOLOGICAL Modified Measles Virus
- BIOLOGICAL Modified Measles Virus Lumbar Puncture
Study Locations (8)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Missouri
- Washington University in St. Louis - St Louis
Ohio
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Utah
- University of Utah - Salt Lake City
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2023-05-10 |
| Phase | Phase 1 |
What the finished NCT02962167 record still lists
NCT02962167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 84-participant average among 9 other Atypical Teratoid/Rhabdoid Tumor trials with a reported enrollment target (60% lower).
The record links to 3 conditions, with Atypical Teratoid/Rhabdoid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Modified Measles Virus is the first listed.
NCT02962167 lists 8 locations in 7 states (California, Illinois, Missouri).
Frequently Asked Questions
What is clinical trial NCT02962167 about?
NCT02962167 is a clinical study titled "Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT". This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid...
What is the current status of trial NCT02962167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-02-22. Estimated completion is 2023-05-10.
What conditions does trial NCT02962167 study?
This clinical trial studies the following conditions: Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent, Medulloblastoma, Childhood, Recurrent.
What interventions are being tested in trial NCT02962167?
The interventions under investigation include: Modified Measles Virus (BIOLOGICAL), Modified Measles Virus Lumbar Puncture (BIOLOGICAL).
Who is sponsoring clinical trial NCT02962167?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02962167 being conducted?
This trial has 8 study locations across California, Illinois, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atypical Teratoid/Rhabdoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02962167's enrollment target sits among peer trials
34 8th of 9 higher than 2 of 9 other Atypical Teratoid/Rhabdoid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atypical Teratoid/Rhabdoid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
-
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI